Financhill
Sell
44

ZVRA Quote, Financials, Valuation and Earnings

Last price:
$8.66
Seasonality move :
-1.31%
Day range:
$8.29 - $8.65
52-week range:
$6.19 - $13.16
Dividend yield:
0%
P/E ratio:
13.52x
P/S ratio:
5.52x
P/B ratio:
3.61x
Volume:
957.6K
Avg. volume:
1.1M
1-year change:
-0.58%
Market cap:
$480.2M
Revenue:
$23.6M
EPS (TTM):
$0.63

Earnings Data

Next earnings date for ZVRA
Mar 10
2026
Most recent earnings per share
-$0.01
Beat by $0.01
(Nov 5/2025)
Consensus Estimate
-$0.02
(Nov 5/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

ZVRA Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
03/10/2026 Q4 $28.1M -- -- $0.05 --
11/05/2025 Q3 $26.6M $26.1M -$0.01 -$0.02 $0.01
08/12/2025 Q2 $22.5M $25.9M $1.36 $1.38 -$0.02
05/07/2025 Q1 $17M $20.4M -$0.06 -$0.18 $0.12
03/11/2025 Q4 $8.9M $12M -$0.67 -$0.40 -$0.27
11/12/2024 Q3 $4.9M $3.7M -$0.70 -$0.41 -$0.29
08/13/2024 Q2 $4.4M $4.4M -$0.48 -$0.44 -$0.04
05/08/2024 Q1 $3.8M $3.4M -$0.40 -$0.48 $0.08
03/28/2024 Q4 $11.7M $13.2M -$0.40 -$0.27 -$0.13
11/07/2023 Q3 $3.4M $2.9M -$0.30 -$0.30 -$0.00
08/14/2023 Q2 -- $8.5M -$0.08 -- --
05/15/2023 Q1 -- $3.2M -$0.38 -- --
03/07/2023 Q4 -- $2M $0.16 -- --
11/09/2022 Q3 -- $2.9M -$0.19 -- --
06/30/2022 Q2 -- $1.3M -$0.70 -- --
03/31/2022 Q1 -- $4M -$0.05 -- --
12/31/2021 Q4 -- $2.6M -$0.08 -- --
09/30/2021 Q3 -- $2M -$0.05 -- --
06/30/2021 Q2 -- $12M -$0.37 -- --
03/31/2021 Q1 -- $12.1M -$2.49 -- --
12/31/2020 Q4 -- $2.4M -$1.07 -- --
09/30/2020 Q3 -- $1.9M -$0.68 -- --
06/30/2020 Q2 -- $6.9M $0.22 -- --
03/31/2020 Q1 -- $2.1M -$1.92 -- --
12/31/2019 Q4 -- $1.4M -$2.88 -- --
09/30/2019 Q3 -- $11.5M $0.96 -- --
06/30/2019 Q2 -- -- -$5.22 -- --
03/31/2019 Q1 -- -- -$7.36 -- --
12/31/2018 Q4 -- -- -$3.20 -- --
09/30/2018 Q3 -- -- -$15.04 -- --
06/30/2018 Q2 -- -- -$14.56 -- --
03/31/2018 Q1 -- -- -$28.32 -- --
12/31/2017 Q4 -- -- -$11.52 -- --
09/30/2017 Q3 -- -- -$10.88 -- --
06/30/2017 Q2 -- -- -$7.04 -- --
03/31/2017 Q1 -- -- -$17.76 -- --
12/31/2016 Q4 -- -- -$10.88 -- --
09/30/2016 Q3 -- -- -$14.72 -- --
06/30/2016 Q2 -- -- -$9.28 -- --
03/31/2016 Q1 -- -- -$3.20 -- --
12/31/2015 Q4 -- -- -$10.24 -- --

Zevra Therapeutics, Inc. Earnings Questions

  • How Much did Zevra Therapeutics, Inc. Generate in Revenue Last Quarter?

    Zevra Therapeutics, Inc. reported $26.1M worth of top line sales in its most recent quarter.

  • Did Zevra Therapeutics, Inc. Beat Earnings Last Quarter?

    Zevra Therapeutics, Inc. announced earnings per share of -$0.01 which represents a beat of analyst forecast a -$0.02 per share.

  • Is Zevra Therapeutics, Inc. Profitable?

    Zevra Therapeutics, Inc. reported $24.5M that represents $0.44 per share over the last quarter.

  • What is the Analyst Consensus for Zevra Therapeutics, Inc. EPS Next Year?

    Zevra Therapeutics, Inc.'s earnings are forecast to decrease from -$2.28 per share to -$1.93 per share next year representing a decrease of -98.25%.

  • When is Zevra Therapeutics, Inc.'s Earnings Date?

    Zevra Therapeutics, Inc.'s next earnings date is March 10, 2026.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
53
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 36x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
60
AAOI alert for Dec 24

Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.

Buy
85
HUT alert for Dec 24

Hut 8 Corp. [HUT] is up 0.65% over the past day.

Buy
63
GPCR alert for Dec 24

Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock